Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).
Abhishek Tripathi(ITM University), Lauren C. Harshman(Dana-Farber Cancer Institute), Gabrielle Bouchard(Dana-Farber Cancer Institute), Charlene Mantia(Dana-Farber Cancer Institute), Xiao X. Wei(Dana-Farber Cancer Institute), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Sabina Signoretti(Brigham and Women's Hospital), Marios Giannakis(Broad Institute), Toni K. Choueiri(Harvard University), Rebecca B. Jennings(IHS Markit (United States)), Connor Gray(Beth Israel Deaconess Medical Center), Bradley A. McGregor(Harvard University), Abdallah Flaifel(Brigham and Women's Hospital), Wanling Xie(Dana-Farber Cancer Institute), Nieves Martínez Chanzá(Institut Jules Bordet), David F. McDermott(Beth Israel Deaconess Medical Center), Justin H. Fleischer(Dana-Farber Cancer Institute), Emily Stern Gatof(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k